Cloherty, Gavin
Chevaliez, Stephane
Sarrazin, Christoph
Herman, Christine
Holzmayer, Vera
Dawson, George
Maasoumy, Benjamin
Vermehren, Johannes
Wedemeyer, Heiner
Feld, Jordan J.
Pawlotsky, Jean-Michel
Article History
Received: 18 May 2016
Accepted: 28 September 2016
First Online: 20 October 2016
Competing interests
: Gavin Cloherty, Kevin Cheng, Christine Herman, Vera Holzmayer, George Dawson and John Hackett are employees and shareholders of Abbott Laboratories. Heiner Wedemeyer has received honoraria for consulting or speaking engagements from Abbott, Abbvie, Biolex, Bristol-Myers Squibb, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Foundation, Gilead Sciences, ITS, JJ/Janssen-Cilag/Janssen TE, Medgenics, Merck/ Schering-Plough, Novartis, Novaria, Roche, Roche Diagnostics, Siemens, Transgene and ViiV. Jean-Michel Pawlotsky has received research grants from Gilead Sciences and has served as an advisor fror Abbott, Abbvie, Achillon, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis and Roche. Christoph Sarrazin has received speaker fees, advisory boards and research support from Abbvie, Roche, Siemens and Qiagen. Stephen Chevaliez has received research grants from Gilead Sciences and has served as an advisor for Gilead Sciences and Roche Pharmaceuticals. Jordan Feld has received consulting fees from Abbvie, Abbott, BMS, Gilead, Janssen, Merck, Theravance. Research support from Abbvie, Abbott, BI, BMS, Gilead, Janssen, Merck, Santaris. Benjamin Maasoumy has received speaker and/or consulting fees from Abbott Molecular, Roche, MSD/Merck, BMS, Fujirebio, Janssen-Cilaq. Research support from Roche and Abbott Molecular. Travel grants from Janssen-Cilaq and Gilead. Johannes Vermehren has received consulting and lecture fees from Abbott, AbbVie, Bristol-Myers Squibb, Covidien, Gilead.